These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 35898799)

  • 41. Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model.
    Rosenke K; Okumura A; Lewis MC; Feldmann F; Meade-White K; Bohler WF; Griffin A; Rosenke R; Shaia C; Jarvis MA; Feldmann H
    bioRxiv; 2022 Feb; ():. PubMed ID: 35233571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fullerene Derivatives for Drug Delivery against COVID-19: A Molecular Dynamics Investigation of Dendro[60]fullerene as Nanocarrier of Molnupiravir.
    Giannopoulos GI
    Nanomaterials (Basel); 2022 Aug; 12(15):. PubMed ID: 35957142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PANORAMIC: important insights into molnupiravir use in COVID-19.
    Kidd MR; Kelly PM
    Lancet; 2023 Jan; 401(10373):250-251. PubMed ID: 36566762
    [No Abstract]   [Full Text] [Related]  

  • 44. Erythema multiforme major associated with molnupiravir treatment for SARS-CoV-2 infection: First report.
    Zengarini C; Epifani V; Baraldi C; Mussi M; Potena L; Giovannini L; Piraccini BM; Pileri A
    J Eur Acad Dermatol Venereol; 2023 Apr; ():. PubMed ID: 37016985
    [No Abstract]   [Full Text] [Related]  

  • 45. Concise two-step chemical synthesis of molnupiravir.
    Pereira VRD; Bezerra MAM; Gomez MRBP; Martins GM; da Silva AD; de Oliveira KT; de Souza ROMA; Amarante GW
    RSC Adv; 2022 Oct; 12(46):30120-30124. PubMed ID: 36329948
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.
    Goswami H; Alsumali A; Jiang Y; Schindler M; Duke ER; Cohen J; Briggs A; Puenpatom A
    Pharmacoeconomics; 2023 May; 41(5):605. PubMed ID: 36928836
    [No Abstract]   [Full Text] [Related]  

  • 47. Safety and efficiency of molnupiravir for COVID-19 patients with advanced chronic kidney disease.
    Dufour I; Devresse A; Scohy A; Briquet C; Georgery H; Delaey P; Greef J; Goffin E; Labriola L
    Kidney Res Clin Pract; 2023 Mar; 42(2):275-278. PubMed ID: 37037486
    [No Abstract]   [Full Text] [Related]  

  • 48. Fluoxetine and Molnupiravir: A Synergistic Combination for COVID-19 Treatment?
    Pashaei Y
    Hosp Pharm; 2022 Oct; 57(5):603-604. PubMed ID: 36081539
    [No Abstract]   [Full Text] [Related]  

  • 49. The effect of molnupiravir on post-acute outcome of COVID-19 survivors.
    Hsu WH; Shiau BW; Tsai YW; Wu JY; Liu TH; Chuang MH; Lai CC
    J Infect; 2023 Oct; 87(4):339-343. PubMed ID: 36958635
    [No Abstract]   [Full Text] [Related]  

  • 50. Discovering common pathogenetic processes between COVID-19 and tuberculosis by bioinformatics and system biology approach.
    Huang T; He J; Zhou X; Pan H; He F; Du A; Yu B; Jiang N; Li X; Yuan K; Wang Z
    Front Cell Infect Microbiol; 2023; 13():1280223. PubMed ID: 38162574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?
    Clark NF; Taylor-Robinson AW; Heimann K
    Ther Adv Drug Saf; 2022; 13():20420986221107753. PubMed ID: 35898799
    [No Abstract]   [Full Text] [Related]  

  • 52. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
    Waters MD; Warren S; Hughes C; Lewis P; Zhang F
    Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
    Yip AJW; Low ZY; Chow VTK; Lal SK
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.
    Kobayashi H; Mori Y; Ahmed S; Hirao Y; Kato S; Kawanishi S; Murata M; Oikawa S
    J Infect Dis; 2023 Apr; 227(9):1068-1072. PubMed ID: 36461940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
    Lee CC; Hsieh CC; Ko WC
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827232
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.